[Clinical evaluation of cefminox, a new cephamycin antibiotic, in the pediatric infections]

Area of Science:

• Pediatric Infectious Diseases
• Pharmacology
• Bacteriology

Background:

• Bacterial infections pose a significant health risk in pediatric populations.
• The need for safe and effective antimicrobial agents in children is critical.
• Cefminox (CMNX) is a cephalosporin antibiotic with potential applications in pediatric care.

Purpose of the Study:

• To evaluate the safety and efficacy of Cefminox (CMNX) in pediatric patients.
• To determine the clinical outcomes of CMNX treatment for various bacterial infections in children.
• To assess the pharmacokinetic profile of CMNX in pediatric subjects.

Main Methods:

• A study involving fifteen pediatric cases with bacterial infections.
• Treatment administered via intravenous bolus injections of Cefminox (CMNX) at doses ranging from 30 to 100 mg/kg/day.
• Infections included acute respiratory tract, urinary tract, and gastrointestinal infections.

Main Results:

• A 100% cure rate was achieved across all fifteen treated cases.
• No adverse reactions or side effects were reported during the Cefminox (CMNX) therapy.
• The serum half-life of CMNX in children was determined to be approximately 1.5 to 2 hours post-injection.

Conclusions:

• Cefminox (CMNX) demonstrates significant safety and efficacy in treating susceptible bacterial infections in children.
• Intravenous administration of CMNX is well-tolerated in the pediatric population.
• CMNX represents a promising therapeutic option for pediatric bacterial infections.